Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion

Bone

Volumn 48, Issue 3, 2011, Pages 578-587

  Virk, Mandeep S ^a   Alaee, Farhang ^a   Petrigliano, Frank A ^b   Sugiyama, Osamu ^a   Chatziioannou, Arion F ^b   Stout, David ^b   Dougall, William C ^c   Lieberman, Jay R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California at Los Angeles ^*  (United States)

Author keywords

Bone metastasis; Bone morphogenetic proteins; Intratibial injection model of bone metastasis; Mixed osteolytic osteoblastic skeletal lesion; Prostate cancer; RANK Fc

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B FC FUSION PROTEIN; RETRONOGGIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LESION; BONE METASTASIS; BONE TUMOR; CANCER CELL; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HINDLIMB TUMOR; HUMAN; HUMAN CELL; MALE; MIXED LYTIC BLASTIC BONE LESION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PROSTATE CANCER; PROTEIN TARGETING; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE RESORPTION; CELL LINE, TUMOR; FLUORODEOXYGLUCOSE F18; HINDLIMB; HUMANS; MALE; MICE; MICE, SCID; OSTEOCLASTS; OSTEOGENESIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIBIA; TUMOR BURDEN; X-RAY MICROTOMOGRAPHY;

EID: 79751528792     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.11.003     Document Type: Article

References (60)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics. CA Cancer J Clin 2010, 60(5):277-300.
2. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
3. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
4. Roudier M.P., Morrissey C., True L.D., Higano C.S., Vessella R.L., Ott S.M. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008, 180:1154-1160.
5. Lieberman J.R., Daluiski A., Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002, 84-A:1032-1044.
6. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
7. Li X., Cao X. BMP signaling and skeletogenesis. Ann NY Acad Sci 2006, 1068:26-40.
8. Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003, 21:62-72.
9. Bobinac D., Maric I., Zoricic S., Spanjol J., Dordevic G., Mustac E., et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 2005, 46:389-396.
10. Brubaker K.D., Corey E., Brown L.G., Vessella R.L. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004, 91:151-160.
11. Autzen P., Robson C.N., Bjartell A., Malcolm A.J., Johnson M.I., Neal D.E., et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998, 78:1219-1223.
12. Masuda H., Fukabori Y., Nakano K., Takezawa Y., Suzuki T.C., Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003, 54:268-274.
13. Feeley B.T., Gamradt S.C., Hsu W.K., Liu N., Krenek L., Robbins P., et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005, 20:2189-2199.
14. Harris S.E., Harris M.A., Mahy P., Wozney J., Feng J.Q., Mundy G.R. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994, 24:204-211.
15. Yang S., Zhong C., Frenkel B., Reddi A.H., Roy-Burman P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005, 65:5769-5777.
16. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T., et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997, 57:5022-5027.
17. Ye L., Lewis-Russell J.M., Kyanaston H.G., Jiang W.G. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007, 22:1129-1147.
18. Ye L., Kynaston H., Jiang W.G. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J Urol 2009, 181:2749-2759.
19. Morrissey C., Brown L.G., Pitts T.E., Vessella R.L., Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010, 12(2):192-205.
20. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005, 65:8274-8285.
21. Rosen V. BMP and BMP inhibitors in bone. Ann NY Acad Sci 2006, 1068:19-25.
22. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002, 420:636-642.
23. Feeley B.T., Liu N.Q., Conduah A.H., Krenek L., Roth K., Dougall W.C., et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006, 21:1571-1580.
24. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008, 34:92-101.
25. Keller E.T. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002, 38:91-102.
26. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
27. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
28. Dougall W.C., Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006, 25:541-549.
29. Hofbauer L.C., Neubauer A., Heufelder A.E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001, 92:460-470.
30. Michigami T., Ihara-Watanabe M., Yamazaki M., Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001, 61:1637-1644.
31. Kitazawa S., Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002, 198:228-236.
32. Higano C.S. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004, 31:331-352.
33. Eaton C.L., Coleman R.E. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 2003, 29:189-198.
34. Hatoum H.T., Lin S.J., Smith M.R., Barghout V., Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113:1438-1445.
35. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005, 4:31-37.
36. Body J.J., Lipton A., Gralow J., Steger G.G., Gao G., Yeh H., et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 2010, 25(3):440-446.
37. Ignatoski K.M., Escara-Wilke J.F., Dai J.L., Lui A., Dougall W., Daignault S., et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008, 68:820-829.
38. Zhang J., Dai J., Yao Z., Lu Y., Dougall W., Keller E.T. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003, 63:7883-7890.
39. Virk M.S., Petrigliano F.A., Liu N.Q., Chatziioannou A.F., Stout D., Kang C.O., et al. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 2009, 44:160-167.
40. Lee Y.P., Schwarz E.M., Davies M., Jo M., Gates J., Zhang X., et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002, 62:5564-5570.
41. Whang P.G., Schwarz E.M., Gamradt S.C., Dougall W.C., Lieberman J.R. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005, 23:1475-1483.
42. Miller R.E., Roudier M., Jones J., Armstrong A., Canon J., Dougall W.C. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008, 7:2160-2169.
43. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
44. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
45. Virk M.S., Lieberman J.R. Tumor metastasis to bone. Arthritis Res Ther 2007, 9(Suppl 1):S5.
46. Hall C.L., Bafico A., Dai J., Aaronson S.A., Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65:7554-7560.
47. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44: 91-103 Jul 1;44(2).
48. Hsu W.K., Virk M.S., Feeley B.T., Stout D.B., Chatziioannou A.F., Lieberman J.R. Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model with using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med 2008.
49. Feeley B.T., Krenek L., Liu N., Hsu W.K., Gamradt S.C., Schwarz E.M., et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38:154-166.
50. Peng H., Chen S.T., Wergedal J.E., Polo J.M., Yee J.K., Lau K.H., et al. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. Mol Ther 2001, 4:95-104.
51. Hawkins R.A., Choi Y., Huang S.C., Hoh C.K., Dahlbom M., Schiepers C., et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992, 33:633-642.
52. Loberg R.D., Gayed B.A., Olson K.B., Pienta K.J. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005, 96:439-446.
53. Vessella R.L., Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006, 12:6285s-6290s.
54. Canon J., Bryant R., Roudier M., Osgood T., Jones J., Miller R., Coxon A., Radinsky R., Dougall W.C. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010, 46(6):1613-1619.
55. Holland P.M., Miller R., Jones J., Douangpanya H., Piasecki J., Roudier M., Dougall W.C. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 2010, 9(7):539-550.
56. Schwaninger R., Rentsch C.A., Wetterwald A., van der Horst G., van Bezooijen R.L., van der Pluijm G., et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 2007, 170:160-175.
57. Saad F., Clarke N., Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006, 49:429-440.
58. Chirgwin J.M., Mohammad K.S., Guise T.A. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004, 4:308-318.
59. Guise T.A., Yin J.J., Mohammad K.S. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003, 97:779-784.
60. Berger F., Lee Y.P., Loening A.M., Chatziioannou A., Freedland S.J., Leahy R., et al. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging 2002, 29:1225-1236.